Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)
May 19 2022 - 4:31PM
Edgar (US Regulatory)
Filed by Biotech Acquisition Company
pursuant to Rule 425 under the U.S. Securities Act
of 1933, as amended,
under the Securities Exchange Act of 1934, as amended
Subject Company: Biotech Acquisition Company
Commission File No.: 001-39935
Date: May 19, 2022
On May 19, 2022, Blade shared the following on its LinkedIn page:
The American Thoracic Society 2022 International Conference is a
wrap! Thank you to everyone who took the time to interact with the Blade team at our poster presentations and exhibit booth. After hearing
from so many people throughout the meeting, we could not be more excited to work with the respiratory community to bring life-changing
treatments to patients.
And #ICYMI, check out our news from #ATS2022 by visiting https://lnkd.in/gbPJtcjQ
Hashtags: Wendye Robbins American Thoracic Society #tbt #ipf #fibrosis
#clinicalresearch #clinicaldevelopment
IMPORTANT LEGAL INFORMATION
The foregoing information and statements contained in this Rule 425 filing
are qualified in their entirety by the disclaimers set forth on the Form 8-K filed by Biotech Acquisition Company with the SEC on November
8, 2021.
Biotech Acquisition (NASDAQ:BIOT)
Historical Stock Chart
From Dec 2024 to Jan 2025
Biotech Acquisition (NASDAQ:BIOT)
Historical Stock Chart
From Jan 2024 to Jan 2025